Supplemental Figures 1-5 from Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo
Year: 2023
Type: supplementary-materials
Abstract: Includes additional Western blots, isobolograms, and cell survival assays. Figure S1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in cellular proliferation and growth; Figure S2. (A) MTS assays on additional cell lines (e.g. H23, SK-LU-1, and Calu-1) were performed with increasing concentrations of both MEKi and CDKi; Figure S3. . Cells were treated with various concentrations of GSK1120212 in combination with PD0332991 for 72 hours, and cell viability was measured by MTS assay (left); Figure S4. Isobologram for the combination of GSK1120212 with PD0332991 in A549 and H460 cell lines; Figure S5. MEK inhibitor enhances radiosensitivity of KRAS mutant NSCLC cell lines.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361919082